987 results on '"Kwak, Larry W."'
Search Results
52. Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
53. Development of a Novel Platform for in-Vitro Immune-Monitoring of Antigen-Specific T Cells and Discovery of Novel Antigen-Specific TCRs Using Immortalized B Cells Transfected with mRNA of Antigen Fused to Mitd (IBMAM)
54. Conclusion
55. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
56. Translational Development of Therapeutic Vaccines for Lymphoma
57. Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma
58. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma
59. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
60. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation
61. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol
62. Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.
63. Immunological Approaches to Multiple Myeloma
64. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial
65. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP
66. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
67. Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T-cell immunity
68. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas
69. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
70. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities
71. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma
72. Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events
73. Rush Hour Traffic: Directing T Cells to Tumor
74. Translational development of vaccination strategies in follicular NHL
75. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma
76. Dose-Related Safety and Immunogenicity of Baculovirus-Expressed Trivalent Influenza Vaccine: A Double-Blind, Controlled Trial in Adult Patients with Non-Hodgkin B Cell Lymphoma
77. Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade
78. CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia
79. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice
80. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
81. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
82. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
83. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells
84. Follicular lymphoma: A model of lymphoid tumor progression in man
85. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell–, and not B cell–, dependent antilymphoma immunity
86. Myeloma cell line–derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma
87. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
88. Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach
89. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells
90. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T–cell function in follicular lymphoma
91. 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
92. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone
93. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
94. Double hit lymphoma: the MD Anderson Cancer Center clinical experience
95. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
96. Avelumab (A) Plus Utomilumab (U) in Combination with RICE (rituximab, ifosfamide, carboplatin, etoposide) As a Second-Line Therapy for Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
97. Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP
98. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma
99. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
100. Anti–β2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.